# Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin

> **NCT03234153** · PHASE2 · TERMINATED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 6 (actual)

## Conditions studied

- Muscle-invasive Bladder Cancer

## Interventions

- **DRUG:** Durvalumab (Imfinzi)
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT03234153
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-15
- **Primary completion:** 2019-11-08
- **Final completion:** 2020-05-18
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2020-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03234153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03234153, "Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03234153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*